SCHEMBL5281498

SCHEMBL5281498

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 3/20 0.42
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 4/20 0.37
CYP3A4 P08684 3/20 0.37
NR1H3 Q13133 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE4B Q07343 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134961 0.96 C5AR1 (0.43) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5136154 0.93 C5AR1 (0.41) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5071843 0.93 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5135308 0.92 C5AR1 (0.41) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5069993 0.92 C5AR1 (0.39) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5135238 0.91 C5AR1 (0.45) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5072433 0.90 C5AR1 (0.43) C5AR1TSHR
SCHEMBL5134561 0.89 C5AR1 (0.45) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5134968 0.89 C5AR1 (0.42) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5136494 0.88 P2RX7 (0.41) C5AR1TSHRALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed